Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00050817
Registration number
NCT00050817
Ethics application status
Date submitted
20/12/2002
Date registered
23/12/2002
Date last updated
23/04/2012
Titles & IDs
Public title
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)
Query!
Scientific title
A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low-dose ASA.
Query!
Secondary ID [1]
0
0
EFC4505
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Arteriosclerosis
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - clopidogrel (SR25990)
Treatment: Drugs: clopidogrel (SR25990)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Occurrence of myocardial infarction,stroke or cardiovascular death.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [1]
0
0
severe bleeding
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Eligibility
Key inclusion criteria
INCLUSION:
Be at least 45 years old and comply with at least one of the four categories of inclusion
criteria:
- Combination of atherothrombotic risk factors (2 major or 3 minor or 1 major + 2 minor
risk factors among those listed below)
Major atherothrombotic risk factors
- Type I or II diabetes (under drug therapy)
- Diabetic nephropathy
- Ankle brachial index (ABI) < 0.9
- Asymptomatic carotid stenosis >= 70%
- At least one carotid plaque as evidenced by intima-media thickness (IMT)
Minor atherothrombotic risk factors
- Systolic blood pressure (SBP) >= 150 mmHg, despite appropriate therapy for at least 3
months
- Primary hypercholesterolemia
- Current smoking > 15 cigarettes per day
- Male >= 65 years
- Female >= 70 years
and/or
- Documented cerebrovascular disease (TIA or IS within 5 years) and/or
- Documented coronary artery disease (stable angina with documented multivessel coronary
disease, previous documented MI, multivessel PCI or CABG within 1 year, multivessel
CABG older than 1 year associated with current angina) and/or
- Documented symptomatic PAD
EXCLUSION:
- Absolute indication for the use of clopidogrel, high-dose aspirin (>162 mg), NSAIDs,
or oral anti-thrombotic drugs
- Absolute contraindication to the use of clopidogrel or aspirin
- Clinical conditions likely to interfere with follow-up leading to inability to
complete the trial
Query!
Minimum age
45
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2002
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2005
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
15603
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Sanofi-aventis Administrative Office - Macquarie Park
Query!
Recruitment postcode(s) [1]
0
0
- Macquarie Park
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Ohio
Query!
Country [2]
0
0
Argentina
Query!
State/province [2]
0
0
Buenos Aires
Query!
Country [3]
0
0
Austria
Query!
State/province [3]
0
0
Wien
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
Diegem
Query!
Country [5]
0
0
Brazil
Query!
State/province [5]
0
0
Sao Paulo
Query!
Country [6]
0
0
Canada
Query!
State/province [6]
0
0
Laval
Query!
Country [7]
0
0
Chile
Query!
State/province [7]
0
0
Santiago
Query!
Country [8]
0
0
Czech Republic
Query!
State/province [8]
0
0
Praha
Query!
Country [9]
0
0
Denmark
Query!
State/province [9]
0
0
Horsholm
Query!
Country [10]
0
0
Finland
Query!
State/province [10]
0
0
Helsinki
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Paris
Query!
Country [12]
0
0
Germany
Query!
State/province [12]
0
0
Berlin
Query!
Country [13]
0
0
Greece
Query!
State/province [13]
0
0
Athens
Query!
Country [14]
0
0
Hong Kong
Query!
State/province [14]
0
0
Causeway Bay
Query!
Country [15]
0
0
Hungary
Query!
State/province [15]
0
0
Budapest
Query!
Country [16]
0
0
Italy
Query!
State/province [16]
0
0
Milano
Query!
Country [17]
0
0
Malaysia
Query!
State/province [17]
0
0
Kuala Lumpur
Query!
Country [18]
0
0
Mexico
Query!
State/province [18]
0
0
Mexico
Query!
Country [19]
0
0
Netherlands
Query!
State/province [19]
0
0
Gouda
Query!
Country [20]
0
0
Norway
Query!
State/province [20]
0
0
Lysaker
Query!
Country [21]
0
0
Poland
Query!
State/province [21]
0
0
Warszawa
Query!
Country [22]
0
0
Portugal
Query!
State/province [22]
0
0
Porto Salvo
Query!
Country [23]
0
0
Russian Federation
Query!
State/province [23]
0
0
Moscow
Query!
Country [24]
0
0
Singapore
Query!
State/province [24]
0
0
Singapore
Query!
Country [25]
0
0
South Africa
Query!
State/province [25]
0
0
Midrand
Query!
Country [26]
0
0
Spain
Query!
State/province [26]
0
0
Barcelona
Query!
Country [27]
0
0
Sweden
Query!
State/province [27]
0
0
Bromma
Query!
Country [28]
0
0
Switzerland
Query!
State/province [28]
0
0
Geneva
Query!
Country [29]
0
0
Taiwan
Query!
State/province [29]
0
0
Taipei
Query!
Country [30]
0
0
Turkey
Query!
State/province [30]
0
0
Istanbul
Query!
Country [31]
0
0
United Kingdom
Query!
State/province [31]
0
0
Guildford Surrey
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
RATIONALE:
- Atherothrombosis is a progressive and generalized vascular disease resulting in events
leading to myocardial infarction (heart attack), stroke, and vascular death.
- In patients at risk for this disease, it is characterized by an unpredictable, sudden
disruption of atherosclerotic plaques, which may lead to total occlusion of artery due
to formation of a clot. The use of aspirin (blood thinner agent) for reducing those
major ischemic events is either indicated, or recommended by international guidelines.
However, aspirin fails to prevent a high percentage of such life-threatening events.
Therefore, more effective blood thinning therapy may provide additional clinical benefit
to such patients.
- The results of the CURE trial in patients with unstable angina demonstrate the
additional benefit of long-term treatment (up to one year) with clopidogrel, (a blood
thinner agent), when administered in combination with standard therapy including
aspirin. The purpose of CHARISMA is to investigate whether a similar clinical benefit of
clopidogrel may apply to a broad population of high-risk patients receiving low-dose
aspirin therapy. Such population includes patients with previous cardiovascular,
neurovascular or peripheral arterial manifestations of atherothrombosis and patients
with combinations of recognized risk factors for atherosclerosis.
OBJECTIVES:
- To assess the efficacy of clopidogrel 75 mg once-daily by comparison with a placebo, in
preventing cardiovascular morbidity/mortality. The study will compare the efficacy of
the two regimens in preventing the occurrence of major cardiovascular complications
(stroke, heart attack, cardiovascular death) in high-risk patients who are otherwise
receiving low-dose aspirin therapy (75-162 mg daily).
- To evaluate the safety of clopidogrel in this population, and more specifically the
incidence of fatal or severe bleeding (as per GUSTO definition), in order to estimate
the global benefit of clopidogrel in this patient population.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00050817
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
ICD CSD
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00050817
Download to PDF